Medication adherence in inflammatory bowel disease

Intestinal Research

Volumn 15, Issue 4, 2017, Pages 434-445

  Chan, Webber ^a,b   Chen, Andy ^c   Tiao, Darren ^d   Selinger, Christian ^e   Leong, Rupert ^a  

^a ANZAC Research Institute   (Australia)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Colitis; Crohn disease; Inflammatory bowel disease; Medication adherence; Ulcerative

Indexed keywords

EID: 85031925248     PISSN: 15989100     EISSN: 22881956     Source Type: Journal    
DOI: 10.5217/ir.2017.15.4.434     Document Type: Review

References (64)

1. Morisky DE. Facilitating treatment adherence: a practitioner's guidebook. Patient Educ Couns 1988;12:173-175
2. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, 2003
3. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know. Med Care 2005;43:517-520
4. Sackett DL, Haynes RB. Compliance with therapeutic regimens. Baltimore: The Johns Hopkins University Press, 1976
5. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 2012;73:691-705
6. Jackson CA, Clatworthy J, Robinson A, Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol 2010;105:525-539
7. Kawakami A, Tanaka M, Nishigaki M, et al. Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. J Gastroenterol 2013;48:1006-1015
8. Kim SB, Kim KO, Jang BI, et al. Patients' beliefs and attitudes about their treatment for inflammatory bowel disease in Korea. J Gastroenterol Hepatol 2016;31:575-580
9. Spekhorst LM, Hummel TZ, Benninga MA, van Rheenen PF, Kindermann A. Adherence to oral maintenance treatment in adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2016;62:264-270
10. Jeganathan J, Lee CH, Rahme A, et al. Medication adherence in transitional inflammatory bowel disease patients: a multicenter pilot study. J Gastroenterol Hepatol 2014;29:111
11. Selinger C, Robinson A, Leong R. Non-adherence to inflammatory bowel disease maintenance medication: extent and predictors. J Gastroenterol Hepatol 2011;26:116
12. Lopez A, Billioud V, Peyrin-Biroulet C, Peyrin-Biroulet L. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013;19:1528-1533
13. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003;114:39-43
14. Khan N, Abbas AM, Bazzano LA, Koleva YN, Krousel-Wood M. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012;36:755-764
15. van der Have M, Oldenburg B, Kaptein AA, et al. Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study. J Crohns Colitis 2016;10:549-555
16. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008;53:1020-1024
17. Hommel KA, Davis CM, Baldassano RN. Medication adherence and quality of life in pediatric inflammatory bowel disease. J Pediatr Psychol 2008;33:867-874
18. Horváth G, Farkas K, Hollósi R, et al. Is there any association between impaired health-related quality of life and non-adherence to medical therapy in inflammatory bowel disease? Scand J Gastroenterol 2012;47:1298-1303
19. Perry J, Chen A, Collins G, Chang J, Kohler F, Leong R. Medication non-adherence in inflammatory bowel diseases is significantly associated with disability. J Gastroenterol Hepatol 2015;30(Suppl 3):135-136
20. Robinson A, Hankins M, Wiseman G, Jones M. Maintaining stable symptom control in inflammatory bowel disease: a retrospective analysis of adherence, medication switches and the risk of relapse. Aliment Pharmacol Ther 2013;38:531-538
21. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004;53:1123-1128
22. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-646
23. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713
24. Haines ML, Ajlouni Y, Irving PM, et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1301-1307
25. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990;150:1509-1510
26. Fong S, Ward MG, Nasr I, et al. PWE-111 higher red blood cell methotrexate polyglutamates correlate with increased disease activity, and are useful in assessing adherence. Gut 2014;63(Suppl 1):A173
27. Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007;29:619-625
28. Egan LJ, Sandborn WJ, Tremaine WJ, et al. A randomized doseresponse and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999;13:1597-1604
29. Gifford AE, Berg AH, Lahiff C, Cheifetz AS, Horowitz G, Moss AC. A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. Am J Gastroenterol 2013;108:249-255
30. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-1090
31. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006;15:565-574
32. Straka RJ, Fish JT, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997;17:126-132
33. Nguyen TM, La Caze A, Cottrell N. What are validated selfreport adherence scales really measuring? A systematic review. Br J Clin Pharmacol 2014;77:427-445
34. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986;24:67-74
35. Morisky DE, DiMatteo MR. Improving the measurement of selfreported medication nonadherence: final response. J Clin Epidemiol 2011;64:262-263
36. Morisky DE, Malotte CK, Choi P, et al. A patient education program to improve adherence rates with antituberculosis drug regimens. Health Educ Q 1990;17:253-267
37. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10:348-354
38. Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011;17:599-604
39. Kane S, Becker B, Harmsen WS, Kurian A, Morisky DE, Zinsmeister AR. Use of a screening tool to determine nonadherent behavior in inflammatory bowel disease. Am J Gastroenterol 2012;107:154-160
40. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17:17-32
41. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007;102:1417-1426
42. Horne R, Parham R, Driscoll R, Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009;15:837-844
43. Selinger CP, Eaden J, Jones DB, et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2199-2206
44. Severs M, Zuithoff PN, Mangen MJ, et al. Assessing self-reported medication adherence in inflammatory bowel disease: a comparison of tools. Inflamm Bowel Dis 2016;22:2158-2164
45. Moss AC, Lillis Y, Edwards George JB, et al. Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. Am J Gastroenterol 2014;109:1850-1855
46. Horne R. Representations of medication and treatment: advances in theory and measurement. In: Petrie KJ, Weinman JA, eds. Perceptions of health and illness: current research and applications. London: Harwood Academic Press, 1997:155-187
47. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24
48. Waters BM, Jensen L, Fedorak RN. Effects of formal education for patients with inflammatory bowel disease: a randomized controlled trial. Can J Gastroenterol 2005;19:235-244
49. Tiao DK, Jeganathan J, Chen A. et al. Impact of targeted pharmacist counselling intervention on IBD medication adherence. J Gastroenterol Hepatol 2014;29:106
50. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007;167:540-550
51. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003;1:170-173
52. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009;7:762-769
53. Suzuki Y, Iida M, Ito H, et al. 2.4 g Mesalamine (Asacol 400 mg tablet) once daily is as effective as three times daily in maintenance of remission in ulcerative colitis: a randomized, noninferiority, multi-center trial. Inflamm Bowel Dis 2017;23:822-832
54. Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR. The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence 2012;6:127-135
55. Greenley RN, Gumidyala AP, Nguyen E, et al. Can you teach a teen new tricks? Problem solving skills training improves oral medication adherence in pediatric patients with inflammatory bowel disease participating in a randomized trial. Inflamm Bowel Dis 2015;21:2649-2657
56. Cook PF, Emiliozzi S, El-Hajj D, McCabe MM. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns 2010;81:182-186
57. Elkjaer M, Shuhaibar M, Burisch J, et al. E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. Gut 2010;59:1652-1661
58. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis 2011;17:1874-1881
59. Hommel KA, Herzer M, Ingerski LM, Hente E, Denson LA. Individually tailored treatment of medication nonadherence. J Pediatr Gastroenterol Nutr 2011;53:435-439
60. Hommel KA, Hente EA, Odell S, et al. Evaluation of a groupbased behavioral intervention to promote adherence in adolescents with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2012;24:64-69
61. Aguas Peris M, Del Hoyo J, Bebia P, et al. Telemedicine in inflammatory bowel disease: opportunities and approaches. Inflamm Bowel Dis 2015;21:392-399
62. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed webbased solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2014;20:2276-2285
63. Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT). Inflamm Bowel Dis 2012;18:1018-1025
64. Hommel KA, Hente E, Herzer M, Ingerski LM, Denson LA. Telehealth behavioral treatment for medication nonadherence: a pilot and feasibility study. Eur J Gastroenterol Hepatol 2013;25:469-473